Objective: To explore the effect of edaravone on reducing oxidative stress and anti-myocardial fibrosis.
Method: 50 8-week-old male SD rats were randomly divided into 5 groups (control group, model group, edaravone low, medium, and high concentration groups). A rat model of myocardial fibrosis was constructed using isoproterenol (ISO), and each dose of edaravone (Eda) was simultaneously treated with edaravone for 14 days. On day 15, the degree of myocardial fibrosis, left ventricular mass index (LVMI), collagen volume fraction (CVF) and myocardial tissue type I and III collagen (Col I, Col III), hydroxyproline (Hyp), Superoxide was used to detect the content of dismutase (SOD), malondialdehyde (MDA) and nitric oxide (NO) by immunofluorescence and western blotting, and to detect the expression of TGF-β1 in myocardial tissue.
Result: The CVF and LVMI of the model group were significantly higher than those of the control group (P both 0.000). As the therapeutic concentration of edaravone group increased (low, medium and high concentration), CVF and LVMI tended to decrease (P≥0.05); Col I, Col III and Hyp in the model group were more significant than those in the control group. Higher than (P 0.000), the concentration of Col, Col III and Hyp showed a downward trend, the MDA of the model group was significantly higher than that of the control group (P = 0.000), and the levels of SOD and NO were higher than that of the control group. Significantly reduced (P 0.000); SOD and NO in the low, medium, and high concentration groups of edaravone were significantly higher than those of the model group (P\u003c0.05); TGF-β1 of the model group was higher than that of the control group The low, medium and high concentration groups are higher (P = 0.000) and TGF-β1 is significantly lower than the model group; MDA is positively correlated with LVMI, CVF, Col I, Col III and Hyp, SOD and NO are both related to LVMI, CVF , Col I, Col III, Hyp are negatively correlated. TGF-β1 is positively correlated with LVMI, CVF, Col I, Col III, Hyp and MDA, but negatively correlated with SOD and NO.
Conclusion: Edaravone can slow down myocardial fibrosis by reducing oxidative stress and inhibiting the expression of TGF-β1.